On August 18, at the official ceremony in Gorky Park, along with other participants, the status of a resident of the Skolkovo Fund Innovation Centre was given to a portfolio company of Maxwell Biotech Group — MetaMax, Ltd.
MetaMax, Ltd is a Russian biotechnological company, financed by Maxwell Biotech Venture Fund, set up with the participation of RVC. The company was founded in 2010 with the purpose of development and promotion of innovation biopharmaceutical drugs for the treatment of the most wide spread and dangerous systemic diseases. The first product, developed by the company, is MM-D37K, an innovative Russian drug for the treatment of colorectal cancer, one of the most wide spread oncologic diseases in Russia and all over the world.
The preclinical efficiency of the developed drug has already been demonstrated in different tumour models. In addition, the preclinical trials showed an additive and cumulative effect of MM-D37K in combination with standard chemotherapeutic agents.
Andrey Boldyrev, CEO of MetaMax: “Positive evaluation by the experts of the Skolkovo Innovation Centre and acquisition of a resident status by the company confirm the compliance of this development with the highest technological and investment standards. We hope that the further successful accomplishment of the clinical trials by MetaMax and the registration of the drug will make it possible to bring to the Russian and international market a new drug that can improve the quality of life of patients with oncologic diseases, including those with metastatic forms of cancer”.
The projected MM-D37K drug is a special case of a technological platform on the basis of internalized peptide sequences. Within the framework of the platform development MetaMax plans to carry out R&D work, aimed at the search of new peptide sequences, which will make it possible to enlarge the portfolio of the company by means of adding new drugs for the treatment of pancreatic cancer, bladder cancer, kidney cancer and glioblastoma.